BLAUVELT, A. .; SOFEN, H. .; LAMBERT, J. .; MEROLA, J. F. .; LEBWOHL, M. .; HOYT, K. .; BANERJEE, S.; SCHARNITZ, T. .; CROWLEY, J. J. . Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data . SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 4, p. s405, 2024. DOI: 10.25251/skin.8.supp.405. Disponível em: https://jofskin.org/index.php/skin/article/view/2855. Acesso em: 23 jul. 2024.